Genmab AS EBITDA vs. Operating Margin
| GNMSF Stock | USD 224.97 1.96 0.86% |
For Genmab AS profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Genmab AS to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Genmab AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Genmab AS's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Genmab AS over time as well as its relative position and ranking within its peers.
Genmab |
Genmab AS Operating Margin vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Genmab AS's current stock value. Our valuation model uses many indicators to compare Genmab AS value to that of its competitors to determine the firm's financial worth. Genmab AS is one of the top stocks in ebitda category among its peers. It also is one of the top stocks in operating margin category among its peers . The ratio of EBITDA to Operating Margin for Genmab AS is about 11,302,263,648 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genmab AS's earnings, one of the primary drivers of an investment's value.Genmab Operating Margin vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Genmab AS |
| = | 4.24 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Genmab AS |
| = | 0.38 % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Genmab Operating Margin Comparison
Genmab AS is currently under evaluation in operating margin category among its peers.
Genmab AS Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Genmab AS, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Genmab AS will eventually generate negative long term returns. The profitability progress is the general direction of Genmab AS's change in net profit over the period of time. It can combine multiple indicators of Genmab AS, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.
Genmab Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Genmab AS. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Genmab AS position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Genmab AS's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Genmab AS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Use Investing Themes to Complement your Genmab AS position
In addition to having Genmab AS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run RUB Crypto Assets Thematic Idea Now
RUB Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in Russian Ruble. The RUB Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize RUB Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis. For more detail on how to invest in Genmab Pink Sheet please use our How to Invest in Genmab AS guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
To fully project Genmab AS's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Genmab AS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Genmab AS's income statement, its balance sheet, and the statement of cash flows.